SkinBioTherapeutics PLC (AIM:SBTX) chief excutive Stuart Ashman speaks to Proactive after announcing the raising of £2.5mln via a placing of new shares.
He reveals what the company intends to do with the new funding, that may be augmented by a further £1mln from a retail offer.
Ashman says that SkinBioTherapeutics "has always been and always will continue to be flexible enough to adapt to opportunities as and when they come [its] way."